<qa>  What is the name of the first community-based study of direct acting antiviral treatment forAs such, we propose the first community-based, large scale, longitudinal study of directly acting antiviral DAA-based treatment for chronic hepatitis C, set in the District of Columbia. Within this study, approximately 600 HCV genotype 1 monoinfected and HCVHIV coinfected subjects will be treated with ledipasvirsofosbuvir 90 mg400 mg fixed dosed combination for 8-24 weeks, based on the medication labeling instructions, and followed for both immediate SVR12 and long term comorbid disease, cirrhosis, hepatocellular carcinoma, transplantation and mortality outcomes over a 10 year study period. The study will be conducted exclusively in the District of Columbia clinics associated with the NIH DC Partnership for AIDSHIV Progress DC PFAP, which serves a population comprised primarily of minorities, with a high degree of negative predictors of treatment response. In this study, participants will be assigned to treatment either by 1 an ID or hepatology specialist, 2 primary care provider, or 3 physician extender. Please see Figure 1 study schema for an approximate distribution of subjects. Each of these provider groups will undergo uniform training on treatment of hepatitis C and management of adverse events prior to initiation of study. All subjects will sign informed consent and agree to treatment and follow up phases of the study. During the course of the study, subjcts will be clinically evaluated based on American Association for the Study of Liver Diseases AASLD the Infectious Diseases Society of America IDSA guidelines for the management of hepatitis C. Clinical data from subjects will be captured in a city wide cohort database, which will store guideline-driven data points from each clinic visit within the network. 